KT-621, Oral STAT6 Degrader, Phase 1b Results 1 Agenda Introduction Justine Koenigsberg Vice President, Investor Relations Revolutionizing Immunology with Oral Medicines Nello Mainolfi, PhD Founder, President and Chief Executive Officer KT-621 BroADen Phase 1b Data Jared Gollob, MD Chief Medical Officer Closing Remarks Nello Mainolfi, PhD Founder, President and Chief Executive Officer Question and Answer Session 2 Forward Looking Statements This presentation contains forward-looking statements within the me ...

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy December 8, 2025 Forward Looking Statements This presentation discusses an investigational product whose safety and efficacy have not been established. This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regardi ...

Financial Performance & Targets - The company aims for a 12-13% Return on Invested Capital (ROIC) and over $1 billion Free Cash Flow (FCF) by 2028[11] - The company anticipates a 9-10% Trading Profit Compound Annual Growth Rate (CAGR) and 6-7% Organic Revenue CAGR[11] - The company's 12-Point Plan has led to approximately a 300 basis point increase in ROIC, roughly a 14x increase in FCF, and about a 220 basis point increase in Group trading margin[53] Market Position & Strategy (RISE) - The company is well-positioned in attractive markets valued at approximately $50 billion, with a growth rate of 6%[13] - The company's strategy, RISE (Reach more patients, Innovate to enhance the standard of care, Scale through strategic investment, Execute efficiently), aims to elevate the company[57] - The company aims to reach 20 million patients by 2028, an increase of 5 million from the current 15 million[63] Segment Performance & Innovation - In Sports Medicine, the company holds a 25% global market share with a business valued at $1.6 billion in 2024[152] - In Advanced Wound Management, the company holds a 13% global market share in a $13 billion market[14, 255] - The company has launched 78 new products between 2021 and 2025, with over 50% of revenue growth coming from products launched in the last five years[98] Orthopaedics Turnaround - The company is implementing Ortho360 to drive efficiency and profitability in Orthopaedics[83, 383] - The company plans to reduce the number of product families in Orthopaedics to drive greater efficiency[386] - The company is addressing historical overproduction in Orthopaedics, aiming to align supply and demand and improve inventory health[393]

Strategic Rationale - IBM is acquiring Confluent to advance as a software-led hybrid cloud and AI platform company[8] - The acquisition expands IBM's total addressable market (TAM) in the real-time data streaming and event processing market, which is valued at over $100 billion[10, 22] - The deal is expected to be accretive to adjusted EBITDA within the first full year and to free cash flow in year two after closing[11, 28] Confluent Overview - Confluent has approximately 6,500 total customers, with less than 5% having over $1 million in annual recurring revenue (ARR)[14] - Over 40% of Fortune 500 companies have adopted Confluent's technology[14] - Confluent's last twelve months (LTM) revenue exceeds $1 billion[14] Market Drivers - The number of new applications is expected to exceed 1 billion by 2028[21] - 89% of IT leaders consider data streaming platforms critical or important for achieving their data-related goals[21] - Total enterprise AI spending is projected to surpass $800 billion by 2029, more than 3 times the spending in 2024[21] Synergies and Financials - IBM anticipates approximately $500 million in run-rate operational synergies[28] - The transaction has an enterprise value of $11 billion, funded by cash on hand[29] - Confluent's largest shareholders, holding approximately 62% of the voting power, have agreed to vote in favor of the transaction[29, 31]

Z-Rostudirsen Clinical Trial Results - The DELIVER trial of z-rostudirsen in exon 51 DMD met its primary endpoint with a statistically significant increase in dystrophin at 6 months (p<0.0001)[9] - The Registrational Expansion Cohort (REC) replicated a ~7-fold increase in muscle content-adjusted dystrophin from baseline at 6 months with z-rostudirsen 20 mg/kg Q4W (p<0.0001)[32] - Z-Rostudirsen achieved ~10-fold higher level of unadjusted dystrophin relative to the level reported in Phase 3 trial of SoC[37] - The trial showed sustained functional improvement from baseline across multiple clinical endpoints out to 24 months[9] - At 6 months, TTR velocity improved exceeding MCID relative to placebo with nominal p<0.05[42] and 10MWR velocity improved relative to baseline and placebo with nominal p<0.05[45] Safety and Tolerability - Z-rostudirsen has a favorable safety and tolerability profile up to 36 months[59] - 1,062 doses of z-rostudirsen at 20 mg/kg dose level have been administered to date[25] - No participants have persistent related anemia or thrombocytopenia at 20 mg/kg[68] Regulatory and Commercial Strategy - The company plans to submit a BLA for U S Accelerated Approval in Q2 2026[7] - Potential U S launch is anticipated in Q1 2027, assuming FDA grants Priority Review[7] FORCE Platform Validation - The DELIVER trial data validates the potential of the FORCE platform for targeted drug delivery[67]

Wolters Kluwer Investor Teach-In: Artificial Intelligence December 8, 2025 Investor Teach-In: Artificial Intelligence – December 2025 1 Forward-looking statements This presentation contains forward-looking statements. These statements may be identified by words such as "expect", "should", "could", "shall", and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from ...

OPTAGE Inc Summary - OPTAGE's consumer business generated ¥258.3 billion in revenue in FY2024, with 54% from FTTH services, 35% from mobile business, and 11% from business solutions[12] - OPTAGE has 1.7 million FTTH subscribers and 1.37 million mobile subscribers as of end-October 2025[7] - OPTAGE aims to transition to a business portfolio where Business Solutions exceed 50% of revenue by FY2035, targeting approximately ¥430 billion in revenue and ¥75 billion in ordinary profit[68, 69] - OPTAGE plans to invest approximately ¥300 billion in growth areas by 2035 to enhance competitiveness and grow as a core non-energy company[59] Kanden Realty & Development Co,Ltd Summary - Kanden Realty & Development's revenue nearly doubled and profit before taxes increased by 2.8 times from 2016 to 2024[82, 83] - Kanden Realty & Development aims for FY2030 targets of ¥310 billion in revenue, ¥40 billion in profit before taxes, and an ROA of 4.5% or higher[103, 104] - Kanden Realty & Development has established a capital recycling business model, with 50% of on-balance sheet assets allocated to capital recycling as of FY2024[73, 93, 94] - Kanden Realty & Development targets an annual increase of ¥180 billion from FY2026 to FY2030 by strengthening the capital recycling business[99] Nuclear Power Generation Summary - The company supplies approximately 50% of Japan's operating nuclear capacity, with a total of 6,578 MW[113, 114] - The company has invested approximately ¥1.19 trillion in safety measures for all seven plants under the new regulatory standards[115] - The company aims to maximize the utilization of existing reactors and steadily advance the development of next-generation advanced reactors[140]

Transaction Overview - Ageas will acquire 100% ownership of AG Insurance from BNP Paribas Fortis for EUR 1.9 billion[4] - The transaction will be financed via an equity placement of 18.5 million shares at EUR 60 per share, totaling EUR 1.11 billion, along with existing cash and financing facilities[4] - The closing is subject to regulatory approval and is expected in Q2 2026[4] Strategic Rationale - The acquisition offers strategic flexibility and strengthens Ageas' position for potential future inorganic growth opportunities[22, 25] - It allows for further leveraging of AG Insurance's distribution, technical, and operational expertise to deepen group synergies[25] - The deal re-confirms the long-term nature of the bancassurance distribution agreement with BNP Paribas Fortis and deepens collaboration on investments[8, 25, 41] Financial Impact - The transaction is expected to deliver an attractive levered Return on Invested Capital (ROIC) of 15-16%[26, 40] - It is projected to increase HFCF (Holding Free Cash Flow) per share by 7-8% by 2027[26, 33] - The acquisition is expected to provide an immediate uplift of EUR 160-175 million from Belgium and EUR 15 million from the Reinsurance segment starting in 2028[33] Partnership with BNP Paribas - BNP Paribas will maintain a significant stake in Ageas, with a shareholding cap of 25%-1[52] - The partnership is governed by a Relationship Agreement with a 5-year duration and automatic renewal[52] - BNP Paribas supports Ageas' future growth as an independent and autonomous group[52] Elevate27 Targets - The transaction leads to an upgrade of Elevate27 financial targets, including an increase in HFCF and shareholder remuneration[26, 53, 59, 60] - The shareholder remuneration is expected to increase by +10%[60] - HFCF is expected to increase by +13%[59]

Conference Call on Helvetia Baloise Pro Forma Financial Information Matthias Henny, Group CFO Helvetia Baloise 8 December 2025 Overview of contents 2 1) Key messages and preliminary remarks 2) Pro Forma Financial Information 3) Outlook and next milestones 4) Appendix Key messages Merger of equals to form Helvetia Baloise completed on 5 December 2025. Previous communication on benefits of the deal, including on cash and dividend capacity uplift, remain valid. Preparation for operational integration well adva ...

Acquisition Overview - Agreement to acquire a 49% interest in Ohio Utica upstream and midstream assets for $588 million[3, 10] - The acquisition includes approximately 35,000 net acres with over 100 identified gross locations[4, 10] - The asset includes over 140 miles of gathering pipelines and approximately 90 miles of water delivery systems[4, 10] - Expected to close by the end of Q1 2026, with an effective date of July 1, 2025[5, 10] Production and Financial Projections - 2026 net production is estimated at approximately 65 MMcfe per day, with an anticipated growth rate of over 30% CAGR through the end of the decade[4, 10] - Projected cash flow from operations for CY2026 is approximately $100 million net to NOG, with substantial growth projected[10] - Average annual capital spending of approximately $100 million is expected on the asset through the end of the decade[10] Strategic Rationale - The acquisition strategically positions NOG to benefit from global demand growth for gas driven by LNG, AI, and continued growth in power[10, 12] - The integrated midstream system enhances margins, improving combined asset operating costs by over $0.70/mcfe[15] - The midstream cash flows are expected to grow by 140% by the end of the decade[10]